7th Obesity & NASH Drug Development Summit
R&D
Reuniting metabolic experts to enable the assessment of the competitive landscape, the 7th Obesity & NASH Drug Development Summit is your exclusive industry meeting to:
- better understand the state of blood based, imaging and predictive biomarkers to meet primary endpoints and attain regulatory approval
- explore GLP-1 RAs in a new light with FGF21, GIP, Amylin, glucagon receptors and more to lead to better therapeutic profile
- ascertain a safety profile and successfully demonstrate efficacy in combination therapy to accurately assess multiple mechanisms of action
Join 160+ experts from Eli Lilly, Novo Nordisk, Madrigal, Akero, Gilead, Pfizer, AstraZeneca, Gilead, Inventiva, and many more to cultivate sustainable weight-loss drugs and navigate the route towards the first approval in NASH.
